Crohn's & Colitis News

Stay up-to-date with the most current news and information about the Crohn's & Colitis Foundation, as well as Crohn's disease and ulcerative colitis.

Filter results

Greater San Diego & Desert Area Chapter News: August 2019

Check out our August 2019 Chapter Newsletter

August 22, 2019

Meet the Chapter's Newest Addition, McKenna Plant!

The Greater San Diego & Desert Area Chapter is excited to announce that McKenna Plant has joined our team as our new California Education Manager!

August 2, 2019

Greater San Diego & Desert Area Chapter News: June 2019

Read our June 2019 Chapter Newsletter

July 1, 2019

New Research Reveals High Cost of Care for Inflammatory Bowel Disease Patients in the United States

NEW YORK, NY – The cost of care for inflammatory bowel disease (IBD) in the United States has increased significantly over the past five years, according to the results of the Crohn’s & Colitis Foundation’s cost of care study.

May 21, 2019

Crohn's & Colitis Foundation Unveils New Five-Year Research Agenda

NEW YORK, NY – Today, the Crohn’s & Colitis Foundation released its new five-year research agenda to address unmet needs in the inflammatory bowel disease (IBD) research community and provide a roadmap for not only the Foundation but also the IBD research community at-large.

May 16, 2019

2019 Women of Distinction Awards Luncheon

#PartyWithAPurpose: This isn’t your average group of ladies who lunch.

May 2, 2019

Predictimmune and the Crohn’s & Colitis Foundation Announce a Joint Study to Validate and Prove Efficacy of First Prognostic Test for IBD in the US Market

CAMBRIDGE, England—PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today announced details of a jointly sponsored study with the US Crohn’s & Colitis Foundation.

December 4, 2018

Landmark Study to Compare the Effectiveness of Biologic or Small Molecule Therapies in Inflammatory Bowel Disease (IBD) Receives Funding

Crohn’s disease (CD) and ulcerative colitis (UC), collectively referred to as inflammatory bowel disease (IBD), which may affect as many as 3 million Americans, cost over $6 billion annually, and cause substantial patient morbidity, missed work and school, and diminished quality of life. Currently, anti-TNF therapy is considered first line treatment for moderate-to-severe IBD. However, up to 80 percent of patients do not respond or, ultimately, lose response to anti-TNF. New treatments provide additional options from which to choose, however, there are no head-to-head studies that compare these new treatments.

May 17, 2018

Leading Patient & Professional Organizations Announce Funding to Improve Communications & Address Shared Decision-making in Inflammatory Bowel Diseases

The Crohn’s & Colitis Foundation (Foundation) and the American Gastroenterological Association (AGA), in collaboration with Pfizer, Inc., have announced the results of a request for proposal (RFP) to address interventions that aim to improve shared decision-making and promote effective health communication between patients with inflammatory bowel disease (IBD) and their clinicians.

April 17, 2018

The Crohn's & Colitis Foundation Selects Diversigen, Inc. as a Preferred Provider for Metagenomics and Microbiome Analysis Services

Diversigen Inc. is pleased to announce that the company has been selected by the Crohn’s & Colitis Foundation as a preferred provider for metagenomics and microbiome analysis services and to serve as a central lab for the generation of high quality microbiome data to be incorporated into the IBD Plexus® platform.

April 17, 2018